BioCentury | Jan 30, 2020
Distillery Therapeutics

Targeted Bcl-XL degrader identified to treat ALL, TNBC and SCLC

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); breast cancer; small cell lung cancer A University of Florida team led by Dialectic Therapeutics Inc. co-founders Guangrong Zheng and Daohong Zhou showed the company’s lead candidate,...
BioCentury | May 14, 2019
Distillery Therapeutics

GSK3A inhibition restores asparaginase sensitivity in resistant ALL, AML

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting GSK3A could help treat asparaginase-resistant T cell and B cell ALL and AML. In a T...
BioCentury | Jan 4, 2019
Clinical News

FDA approves Servier's ALL therapy acquired in Shire deal

...treat acute lymphoblastic leukemia in patients ages one month to 21 years old. The pegylated L-asparaginase...
BioCentury | Dec 21, 2018
Company News

FDA approves Servier's ALL therapy acquired in Shire deal

...treat acute lymphoblastic leukemia in patients ages one month to 21 years old. The pegylated L-asparaginase...
BioCentury | Nov 9, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Nov. 7 after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran...
BioCentury | Nov 7, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Wednesday after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran and...
BioCentury | Jun 29, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

...ALL treatment options as the reason for stopping the ALL program of Graspa, which comprises L-asparaginase...
...Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP), Lyon, France Product: Graspa eryaspase Business: Cancer Molecular target: NA Description: L-asparaginase...
BioCentury | Jun 25, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

...ALL treatment options as the reason for stopping the ALL program of Graspa, which comprises L-asparaginase...
BioCentury | Apr 20, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

...pegylated L-asparaginase and Onivyde is a nanoparticle liposome formulation of irinotecan. Cal-PEG is a pegylated L-asparaginase...
BioCentury | Apr 16, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

...pegylated L-asparaginase and Onivyde is a nanoparticle liposome formulation of irinotecan. Cal-PEG is a pegylated L-asparaginase...
Items per page:
1 - 10 of 138